Cambridge Scientists Explain 2 GIP Receptor Paths to Weight Loss in Mice
Updated
Updated · ScienceDaily · Aug 15
Cambridge Scientists Explain 2 GIP Receptor Paths to Weight Loss in Mice
2 articles · Updated · ScienceDaily · Aug 15
Summary
Nature Metabolism published mouse data showing GIP receptor activation in the brainstem cut appetite, while blocking the same receptor in the hypothalamus also drove weight loss.
Genetically engineered mice revealed why the opposite approaches can both work: hypothalamic GIP signaling acts as a brake on fullness signals, so blocking it lets satiety cues hit harder.
Drug-combination tests showed GIP-targeting treatments can boost GLP-1 medicines such as Wegovy- and Ozempic-related therapies, and GIP blockade may also strengthen amylin-based drugs.
The findings help explain how obesity drugs with opposite GIP strategies—including Mounjaro and Zepbound on one side and phase 3 MariTide on the other—can produce similar weight-loss effects.
With more than 1 billion people living with obesity, the study points to brain-circuit-specific combinations aimed at greater weight loss with fewer side effects.